ORYN 1051
Alternative Names: ORYN-1051Latest Information Update: 08 Sep 2023
Price :
$50 *
At a glance
- Originator Oryn Therapeutics
- Class Anti-inflammatories; Macrocyclic compounds; Peptides
- Mechanism of Action Immunomodulators; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Crohn's disease; Ulcerative colitis
Most Recent Events
- 06 Sep 2023 Oryn Therapeutics has patent protection for OrynotidesTM(Oryn therapeutics website, September 2023)
- 06 Sep 2023 Preclinical trials in Crohn's disease in USA (Parenteral) (Oryn Therapeutics pipeline, September 2023)
- 06 Sep 2023 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral) (Oryn Therapeutics pipeline, September 2023)